In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bioenvision and Ilex to co-develop clofarabine

Executive Summary

Bioenvison and Ilex Oncology will develop Bioenvision's clofarabine, a nucleoside analog in Phase II clinical trials to treat malignancies such as lymphoma and leukemia, and in Phase I trials for solid tumors. Bioenvision paid Ilex $1.35mm in cash up front.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register